This flexibility has helped 53Biologics to develop a huge variety of processes adapting and developing a broad catalog of recombinant proteins (monoclonal, fusion, chimeric and fragment antibodies, biosimilars, enzymes, anticoagulants, vaccines, etc.) in a wide range of microbial expression systems such as bacteria (E. coli, Bacillus, etc.), yeast (Pichia, Saccharomyces) or fungi (Trichoderma, Aspergillus and the revolutionary C1 , etc.), mammalian expression systems such as CHO, HEK and insect cells like S2. Depending on the protein and process flexibility, each of these processes works differently better in only certain bioreactor configurations.
The upstream process development typically starts with a transference phase of the client’s base case production process, but sometimes the clients do not have an established process or its only at lab (i.e. flask) scale. Then, it is when the experience of 53Biologics represents a huge advantage. The experienced process development team could suggest a first base case for the further optimization that could save time and money for our clients. Only a process fine tune is required to adapt it to each protein of interest.